NewsBenzingaReported Earlier, AstraZeneca’s Alexion Wins US Accelerated Approval For Ultomiris As First C5 Inhibitor To Reduce Proteinuria In IgA Nephropathy Adults; Phase III I CAN Shows 43.4% Reduction Versus Placebo At 34 Weeks Reported Earlier, AstraZeneca’s Alexion Wins US Accelerated Approval For Ultomiris As First C5 Inhibitor To Reduce Proteinuria In IgA Nephropathy Adults; Phase III I CAN Shows 43.4% Reduction Versus Placebo At 34 Weeks Benzinga 2026.10.22 06:49 (GMT+0) Open on Benzinga Other news Tech Stocks Lead Broad Market Lower as Meta Slides -6% Uniswap Aggregator Hooks Go Live on Ethereum, Base and Robinhood Chain Dear Western Digital Stock Fans, Mark Your Calendars for October 22 Claude Duet app is Anthropic’s bet on agents Fireblocks Denies Report of Visa Talks for $2.5B Acquisition, Says Claim Is Untrue Meta (META) Stock Falls 7.02% Intraday, Now at $651.61
